The clinical community is closely watching this innovative therapy, a dual-action modulator targeting both the incretin pathway and another key signal. Early data suggest it may offer meaningful gains in body fat reduction compared to current therapies, potentially representing a major step forward in the battle of excess weight. Continued investig